

1 **Developing an Individualized Clinical Prediction Rules of Antihypertensive Drugs: A Study**
2 **Protocol Based on Real-world Practice**

3

4 Dongsheng Hong^{1,2}; Wendan Shi³; Xiaoyang Lu¹; Wu Jiaying¹; Yan Lou^{1*}; Lu Li^{2*}

5

6 ¹Department of Pharmacy of the First Affiliated Hospital, Zhejiang University School of
7 Medicine, Hangzhou, Zhejiang Province, China.

8 ²Department of Social Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang
9 Province, China.

10 ³Sydney Nursing School, Faculty of Medicine and Health, the University of Sydney, Australia.

11

12 * is the corresponding author, Tel/Fax: 86-571-87232221; E-mail: yanlou@zju.edu.cn; E-mail:
13 lilu@zju.edu.cn

14

15

16

17

18

19

20

21 **Abstract**

22 **Background:** Hypertension is one of the most urgent public health challenges, and drug therapy
23 is the primary method to control blood pressure for patients. However, blood pressure control
24 rate is still poor with antihypertensive drugs use. Although Clinical Prediction Rules (CPR) is
25 useful to help clinicians make more appropriate decisions at the point of medication, the
26 evidence is still limited in china. The objective of this study is to develop an CPR of
27 antihypertensive drugs in individualized application of patients based on real-world practice.

28 **Methods:** A two-way cohort study has been conducted in one China's large tertiary hospital
29 using clinical information on patient characteristics, drug use and clinical outcome. Data
30 extraction is through ICD-10 disease codes of hypertension from Electronic Medical Record
31 System. Eligible patients admitted from September 2016 to August 2018 who have received at
32 least one antihypertensive drug therapy is included. Patients were grouped into several exposure
33 groups according to medications. COX regression model and clinical specialty survey is applied
34 to identify Influencing Factors (IF) in different study groups, and the discriminant model was
35 used to construct a CPR according IF. The accuracy of the CPR is analyzed by sensitivity,
36 specificity, Youden's index and Receiver Operating Characteristic (ROC) curve.

37 **Discussion:** Result is expected to provide valuable CPR for physicians and policymakers with
38 respect to treating hypertension according characteristic of individual patients. By developing a
39 predictive method for clinical outcomes and treatment costs of antihypertensive medication, we
40 expect to discriminate those patients who would profit from specific scheme of antihypertensive
41 drugs to minimal incidence probability of costs and complications in region of china.

42 **Trial registration:** This study was registered at www.chictr.org as a primary register of the
43 WHO International Clinical Trials Registry Platform (ICTRP), and the registered number is
44 ChiCTR1900026339.

45 **Keywords:** Clinical Prediction Rules; Decision support; Hypertension; Medical treatment;
46 Medication optimization

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65 **Highlights**

66 Although Clinical Prediction Rules (CPR) could recognize individual patient risk and help
67 clinicians to make more appropriate decision at the point of medication as part of clinical
68 decision support systems, the evidence in this respect is still limited in China.

69 This study is first going to construct the CPR of multiple antihypertensive drugs in real
70 world practice of China.

71 The highlights of this study is aimed to provide a pragmatic method to support clinical
72 decisions for patients who has received antihypertensive drugs before long-term diagnosis of
73 hypertension in real world practice according to their characteristics that are accessible to
74 clinicians.

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89 1. Background

90 Hypertension is one of the constantly rising global health concerns^{1,2}, and it is considered
91 as the enormous sponsor to the burden of disease³. In China, there are 270 million adults in total
92 who suffered from a condition of hypertension, the Disability-Adjusted Life Year (DALY) has
93 reached 37.94 million people per year⁴. The direct medical expenses for drug treatment are
94 nearly 40 billion Chinese yuan per year, and it is still increasing accordingly⁵. Under such high
95 medical expenditures, the control rate of Blood Pressure (BP) in China is only 16.9%⁵. With the
96 aging population, changes in lifestyle, and population growth⁶, the burden of illness with
97 hypertension is also growing over time.

98 Drug therapy is currently recognized as the primary method of hypertension treatment⁷.
99 However, hypertension is normally an asymptomatic disease⁸. Patients may suffer from side
100 effects of antihypertensive drugs (AHD), which bring about them become worse than they did
101 before using medication. The poor personal response to standard treatment is one of the main
102 reason of low rate of hypertension control⁶, and a large meta-analysis of prospective study stated
103 the relationship between poor personal response (BP levels) and cardiac-cerebral vascular
104 events⁹. To obtain the maximum antihypertensive effect of existing drugs, physicians and
105 policymakers have turned to the rational use of antihypertensive drugs according to the
106 characteristics of individual patient^{10,11}.

107 Although Clinical Decision Support Systems (CDSS) could be effective in providing an
108 appropriate and cost-effective methods to improve the blood pressure control rate with reducing
109 cardiovascular risk^{12,13}. The evidence of CDSS is from clinical guidelines, which major advocate
110 evidence-based recommend and basically use a standard of universal treatment at the population
111 levels¹⁴, are not highly concern to the characteristics of individual patients. Otherwise, AHD is

112 more than 100 varieties in China that may have differences in terms of mechanism of action,
113 dosage, adverse reactions and contraindications. The ability of an individual physician to
114 optimize drug combinations for personal patient is rapidly going beyond their capabilities and
115 comprehension¹⁵. Therefore, the clinical application of AHD should oblige to be person-centered
116 for individual patients. It should balance of clinical effects, adverse reactions, and costs of
117 treatment, in order to deduce which AHD will have the most effectiveness to control BP at an
118 individual level with a good profile.

119 Clinical prediction rules (CPR) as an important component of CDSS, which is focusing
120 particularly on the possible applications of individual characteristics for the evaluation risk of
121 hypertensive patients. However, the evidence of CPR is still poor based on clinical feedback.
122 Accordingly, the aim of this study is to eventually provide evidence of developing an CPR to
123 identify of personal clinical characteristics that will better manage the AHD choice to improve
124 disease control of the individual patient and overall hypertension population.

125 **2. Methods**

126 **2.1 Study design**

127 This research will conduct a two-way cohort study of hypertensive patients at the First
128 Affiliated Hospital of College of Medicine of Zhejiang University in China (FHMZC), where the
129 outpatient volume is moreover three million per year as China regional medical center. The
130 information of Patient's treatment outcomes will be collected prospectively in future, and the
131 participants will be grouped according to their exposure at the time of recruitment. Exposure
132 options are first-line treatment drugs according guidelines for hypertension in China^{16, 17},
133 including Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin Receptor Blocker
134 (ARB), Calcium Channel Blockers (CCB), diuretic, and β -blocker used as alone or in

135 combination. This study will follow the statement of Strengthening the Reporting of
136 Observational Studies in Epidemiology (STROBE), and The STROBE Statement Checklist of
137 cohort studies is shown in online supplementary appendix 1.

138 The study period is planned to be over a 3-year period from 1 September 2016 to 31 August
139 2018. This period has been selected based on the availability of enough patients who would have
140 been exposed to the study hypertensive drugs as well as coinciding with the availability of
141 Electronic Medical Record System (EMRC).

142 **2.2 Study cohort**

143 The source patients include all EMRC patients aged 18 years and over, who has diagnosed
144 with hypertension. Antihypertensive drugs exposure will be defined from dispensed prescription
145 records of EMRC, beginning from 1 September 2016 and until the end of study. New patients
146 using antihypertensive drugs will be determined by using a review observation period of 6
147 months prior to the index prescription date, and which must indicate no hypertensive drugs use
148 during that period. The index date will be identified as the date of the new prescription for
149 antihypertensive drugs. The group of study cohort would be constructed according to the
150 antihypertensive drugs.

151 **2.3 Data extraction**

152 The study obtains data through data extraction of EMRC and follow-up survey. Data
153 extraction will through ICD-10 disease codes¹⁸, including I10.X00, I10.X01, I10.X02, I10.X03,
154 I10.X04, I10.X05, I10.X06, I11.900, I12.903 and I15.000. Information will be collected as the
155 following: (1) demographic information; (2) medical history; (3) duration of illness; (4)
156 underlying diseases; (5) medication history; (6) alcohol intake/smoking history; (7) inspection
157 information; (8) efficacy evaluation; (9) complications.

158 **2.4 Sample size**

159 The sample size of our study is estimated by 10-15 times of the total factor¹⁹. If the factor
160 involved is 30 temporarily, the sample size should be no less than 300 cases for a group. In
161 addition, assuming that the loss rate of cohort study is 20%, the sample size should be further
162 expanded to no less than 375 cases for a group. If the model is constructed according to 375
163 cases and verified by 375 cases, the final requirement is that the sample size should be enlarged
164 to no less than 750 cases for a group.

165 **2.5 Cost assignments and Outcomes measures**

166 Direct costs will be assigned in Chinese Yuan (¥) using EMRC, and the costs is classified
167 into two categories with drug related and costs for medical services. All major outcomes are
168 identified: (1) coronary artery disease, (2) chronic heart failure, (3) renal insufficiency, and (4)
169 cerebrovascular disease²⁰.

170 **2.6 Identification of influencing factors**

171 Data characteristics among patients are commonly believed to be associated with treatment
172 response and outcomes, and disease progression. We will conduct a method of COX regression
173 and clinical specialty survey to identify Influencing Factors (IF) in different study groups of
174 cohort²¹.

175 **2.7 Individualized Clinical Prediction Rules**

176 IF are directly related to medication in patients with hypertension. The discriminant model
177 will be utilized to construct an individualized CPR based on the clinical outcomes and IF, and
178 the clinical outcomes include the cost of treatment and the main outcomes as defined before²².
179 The accuracy of the rules is analyzed by sensitivity, specificity, Youden's index and Receiver
180 Operating Characteristic (ROC) curve²³⁻²⁵.

181 The real-time data of each stage of patients are input into CPR to calculate the treatment
182 cost of different medication schemes and their impact on the treatment outcome of patients under
183 the current condition of exporting patients, so as to assist physicians in choosing Medication
184 drugs for hypertension.

185 **2.8 Statistical analysis**

186 The measurement data of normal distribution are expressed by $M(Q_R)$, the classification
187 data is worked out by relative number, the comparison of continuous variables is analyzed by t-
188 test, the classification variables is calculated by chi-square test, the survival analysis between
189 groups is performed by Kaplan-Meier survival curve and log rank test, and the multivariate
190 analysis is done by Cox regression. The risk grade of hypertension complications was judged by
191 the Risk Ratio (RR) of different medication schemes^{26, 27}. If RR is ranged from 1.2-1.5, the risk
192 factors are indicated with a weak relationship to complications, while an RR of 1.6-2.9 shows
193 moderate relationship to, and an RR of 3.0 and above illustrates strong relationship to the
194 complications. Besides, the accuracy of risk estimation is judged by the 95% Confidence Interval
195 (CI) of RR. Data analysis was carried out by R software (Version 3.5.2, [https://www.r-
196 project.org/](https://www.r-project.org/)).

197 **3. Discussion**

198 Artificial intelligence (AI) is developing rapidly in field medic of china, and CDSS is a
199 typical representative. CPR is a core part of CDSS, which stand for a method of recognizing
200 individual patient of cost and effectiveness to help policymakers make more appropriate
201 decisions at the point of medication^{28, 29}. Although CPR is important in antihypertensive drugs,
202 the evidence in this respect is still limited in region of China.

203 To our knowledge, this trial is a first real-world study in China, in which the occurrence of
204 clinical outcomes and medication costs in patients with antihypertensive drugs will be recorded
205 and the relationship between cost-effectiveness of medication and patient characteristics/
206 therapeutic schedule will be evaluated based on real-world practice. In fact, it has increased its
207 awareness among physicians to provide effective antihypertensive drug scheme according to
208 patient characteristics. Our study will address drug treatment for hypertension in Chinese
209 healthcare facilities, with a particular focus on tertiary hospitals, from a range of real-world
210 perspectives.

211 As a result, we will construct a two-way study cohort according AHD, and the data of each
212 group include socio-demographic characteristics, disease progression, and clinical outcome^{30, 31}.
213 The COX regression model and clinical specialty survey are carried out to identified IF in
214 different study cohorts²¹, and the discriminant model will be used to develop CPR²². To evaluate
215 the effect of different medication regimens and patient characteristics on clinical outcomes
216 according to CPR, and the physicians reasonably choose the medication plan according to the
217 evaluation results.

218 The present analysis is subject to some limitations intrinsic to real world studies, including
219 potential confounding factors³² such as polydrug use among users of antihypertensive drugs^{33, 34},
220 adherence to medication³⁴, and indication bias³⁵ among patients with hypertension. We
221 attempted to minimize these by recruiting the predominant individuals using antihypertensive
222 drugs as the drug of choice within the past six months prior to enrollment to the study.
223 Importantly, it is noted that the emphasis of the study is a pragmatic approach to clinical decision
224 support for patients who must be accept antihypertensive drugs before long diagnosis of

225 hypertension in real world practice according patient characteristics that are accessible to
226 physicians.

227 In summary, our research findings hope to provide valuable CPR for physicians and
228 policymakers with respect to treating hypertension according characteristic of individual patients.
229 By developing a predictive method for clinical outcomes and treatment costs of antihypertensive
230 medication, we expect to discriminate those patients who would profit from specific scheme of
231 antihypertensive drugs to minimal incidence probability of costs and complications.

232 **List of abbreviations**

233 **CPR:** Clinical Prediction Rules; **CDSS:** Clinical Decision Support Systems; **AHD:**
234 Antihypertensive drugs (AHD); **AI:** Artificial intelligence; **IF:** Influencing Factors; **EMRC:**
235 Electronic Medical Record System; **DALY:** Disability-Adjusted Life Year

236 **Declarations**

237 **Ethics approval and consent to participate**

238 Required ethics approvals have been obtained prior to our study from the ethics committee
239 of the First Affiliated Hospital of College of Medicine of Zhejiang University in China, and the
240 committee's reference number is #2019-1391.

241 **Ethics and consent to participate**

242 This study conduct by using previously obtained information, and meet four conditions at
243 the same time, including “It is unrealistic or impossible to obtain informed consent”, “The
244 Privacy of subject could be well protected”, “Not more than the minimum risk” and “The right
245 and interests of subject will not be invaded”. Therefore, after careful ethical review by the ethics
246 committee, this study was approved Informed Consent Waiver (Reference number is #2019-
247 1391).

248 **Availability of data and materials**

249 The datasets used and/or analysis during the current study are available from the
250 corresponding author on reasonable request.

251 **Competing interests**

252 The authors declare that they have no competing interests.

253 **Funding**

254 Not applicable.

255 **Authors' contributions**

256 DSH and YL had the original idea for this study. WDS and JYW reviewed previous studies.
257 XYL interpreted the patient data regarding antihypertensive drugs. XYL and LL Provide
258 statistical support. DHS registered in chictr and is the guarantor of the protocol. All authors read
259 and approved the final version of the article.

260 **Acknowledgments**

261 This study is supported by the Zhejiang Province Key Research and Development Program
262 (2019C04006) and Zhejiang Provincial Natural Science Foundation (LQ20G030025) of China.
263 Not applicable.

264 **Trial registration:**

265 This study was registered at www.chictr.org as a primary register of the WHO International
266 Clinical Trials Registry Platform (ICTRP), and the registered number is ChiCTR1900026339.

267
268
269
270
271
272

273 **Reference**

- 274 1. Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in
275 primary aldosteronism compared with essential hypertension: a systematic review and meta-
276 analysis. *The lancet Diabetes & endocrinology* 2018; 6(1): 41-50.
- 277 2. Beaney T, Schutte AE, Tomaszewski M, et al. May Measurement Month 2017: an analysis of
278 blood pressure screening results worldwide. *The Lancet Global health* 2018; 6(7): e736-e43.
- 279 3. Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China:
280 current features and implications. *Nature reviews Cardiology* 2019; 16(4): 203-12.
- 281 4. Mendis S, Davis S, Norrving B. Organizational update: the world health organization global
282 status report on noncommunicable diseases 2014; one more landmark step in the combat against
283 stroke and vascular disease. *Stroke* 2015; 46(5): e121-2.
- 284 5. Zhang HY, Jian WY, Fang H. [Analysis of substitutional effect of outpatient expenditure on
285 inpatient expenditure in hypertensive patients with rural new cooperative medical scheme].
286 *Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences* 2016; 48(3):
287 472-7.
- 288 6. Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for
289 hypertension. *European heart journal* 2017; 38(15): 1101-1111.
- 290 7. Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. *Trends*
291 *in cardiovascular medicine* 2019.
- 292 8. Thomson P, Dowding D, Swanson V, et al. A computerised guidance tree (decision aid) for
293 hypertension, based on decision analysis: development and preliminary evaluation. *European*
294 *journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of*
295 *the European Society of Cardiology* 2006; 5(2): 146-9.
- 296 9. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-specific
297 relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for
298 one million adults in 61 prospective studies. *Lancet* 2002; 360(9349): 1903-13.

- 299 10. Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Clinical
300 Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. *Clinical*
301 *pharmacokinetics* 2017; 56(9): 987-97.
- 302 11. Yannoutsos A, Kheder-Elfekih R, Halimi JM, Safar ME, Blacher J. Should blood pressure
303 goal be individualized in hypertensive patients? *Pharmacological research* 2017; 118: 53-63.
- 304 12. Anchala R, Kaptoge S, Pant H, Di Angelantonio E, Franco OH, Prabhakaran D. Evaluation
305 of effectiveness and cost-effectiveness of a clinical decision support system in managing
306 hypertension in resource constrained primary health care settings: results from a cluster
307 randomized trial. *Journal of the American Heart Association* 2015; 4(1): e001213.
- 308 13. Van de Velde S, Heselmans A, Delvaux N, et al. A systematic review of trials evaluating
309 success factors of interventions with computerised clinical decision support. *Implementation*
310 *science : IS* 2018; 13(1): 114.
- 311 14. Savoia C, Volpe M, Grassi G, Borghi C, Agabiti Rosei E, Touyz RM. Personalized
312 medicine-a modern approach for the diagnosis and management of hypertension. *Clinical*
313 *science* 2017; 131(22): 2671-85.
- 314 15. Tsigelny IF. Artificial intelligence in drug combination therapy. *Briefings in bioinformatics*
315 2019; 20(4):1434-1448.
- 316 16. Joint Committee for Guideline R. 2018 Chinese Guidelines for Prevention and Treatment of
317 Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and
318 Treatment of Hypertension. *Journal of geriatric cardiology* 2019; 16(3): 182-241.
- 319 17. Muntner P, Carey RM, Gidding S, et al. Potential US Population Impact of the 2017
320 ACC/AHA High Blood Pressure Guideline. *Circulation* 2018; 137(2): 109-18.
- 321 18. Hirsch JA, Nicola G, McGinty G, et al. ICD-10: History and Context. *AJNR American*
322 *journal of neuroradiology* 2016; 37(4): 596-9.

- 323 19. Riley RD, Snell KI, Ensor J, et al. Minimum sample size for developing a multivariable
324 prediction model: PART II - binary and time-to-event outcomes. *Statistics in medicine* 2019;
325 38(7): 1276-96.
- 326 20. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular
327 and renal outcomes: updated systematic review and meta-analysis. *Lancet* 2016; 387(10017):
328 435-43.
- 329 21. Scosyrev E, Glimm E. Power analysis for multivariable Cox regression models. *Statistics in*
330 *medicine* 2019; 38(1): 88-99.
- 331 22. de Souza Vieira EE, Bispo JAM, Silveira L, Jr., Fernandes AB. Discrimination model
332 applied to urinalysis of patients with diabetes and hypertension aiming at diagnosis of chronic
333 kidney disease by Raman spectroscopy. *Lasers in medical science* 2017; 32(7): 1605-13.
- 334 23. Hajian-Tilaki K. The choice of methods in determining the optimal cut-off value for
335 quantitative diagnostic test evaluation. *Statistical methods in medical research* 2018; 27(8):
336 2374-83.
- 337 24. Wu M, Shu Y, Li Z, Liu A. Repeated significance tests of linear combinations of sensitivity
338 and specificity of a diagnostic biomarker. *Statistics in medicine* 2016; 35(19): 3397-412.
- 339 25. Grunkemeier GL, Jin R. Receiver operating characteristic curve analysis of clinical risk
340 models. *The Annals of thoracic surgery* 2001; 72(2): 323-6.
- 341 26. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort
342 studies of common outcomes. *Jama* 1998; 280(19): 1690-1.
- 343 27. Tripepi G, Jager KJ, Dekker FW, Wanner C, Zoccali C. Measures of effect: relative risks,
344 odds ratios, risk difference, and 'number needed to treat'. *Kidney international* 2007; 72(7): 789-
345 91.
- 346 28. Feldstein DA, Hess R, McGinn T, et al. Design and implementation of electronic health
347 record integrated clinical prediction rules (iCPR): a randomized trial in diverse primary care
348 settings. *Implementation science : IS* 2017; 12(1): 37.

- 349 29. Michie S, Thomas J, Johnston M, et al. The Human Behaviour-Change Project: harnessing
350 the power of artificial intelligence and machine learning for evidence synthesis and interpretation.
351 *Implementation science : IS* 2017; 12(1): 121.
- 352 30. Attaei MW, Khatib R, McKee M, et al. Availability and affordability of blood pressure-
353 lowering medicines and the effect on blood pressure control in high-income, middle-income, and
354 low-income countries: an analysis of the PURE study data. *The Lancet Public health* 2017; 2(9):
355 e411-e9.
- 356 31. Chen S, Sudharsanan N, Huang F, Liu Y, Geldsetzer P, Barnighausen T. Impact of
357 community based screening for hypertension on blood pressure after two years: regression
358 discontinuity analysis in a national cohort of older adults in China. *Bmj* 2019; 366: 14064.
- 359 32. Geerligs L, Rankin NM, Shepherd HL, Butow P. Hospital-based interventions: a systematic
360 review of staff-reported barriers and facilitators to implementation processes. *Implementation*
361 *science : IS* 2018; 13(1): 36.
- 362 33. Sabido M, Hohenberger T, Grassi G. Pharmacological intervention in hypertension using
363 beta-blockers: Real-world evidence for long-term effectiveness. *Pharmacological research* 2018;
364 130: 191-7.
- 365 34. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination
366 antihypertensive medications, adherence, and clinical outcomes: A population-based
367 retrospective cohort study. *PLoS medicine* 2018; 15(6): e1002584.
- 368 35. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of
369 cardiovascular disease and death: a systematic review and meta-analysis. *Lancet* 2016;
370 387(10022): 957-67.